Skip to main content

Table 3 Comparison of the BNT162b2 and the ChAdOx1 vaccines for hospitalisation for COVID-19 and death from COVID-19

From: Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

Outcomes

BNT162b2

ChAdOx1

Number

536,371

774,704

Hospitalisation for COVID-19

 Event (n)

603

1,432

 Mean follow-up (months)

6.74

7.41

 Incidence ratea, per 1000 person-months

0.17

0.26

 Rate difference (95%CI) a, per 1000 person-months

-0.09 (-0.13, -0.05)

0.00 (ref)

 Hazard ratio (95% CI) a

0.65 (0.57, 0.74)

1.00 (ref)

Death from COVID-19

 Event (n)

42

112

 Mean follow-up (months)

6.74

7.41

 Incidence ratea, per 1000 person-months

0.018

0.022

 Rate difference (95%CI) a, per 1000 person-months

-0.005 (-0.016, 0.006)

0.00 (ref)

 Hazard ratio (95% CI) a

0.66 (0.42, 1.04)

1.00 (ref)

  1. CI Confidence interval
  2. aEstimates were time-stratified overlap weighted of propensity score